SuperGen stock drops
5th Sep 2005, 15:36 GMT
Shares of SuperGen slid nearly 6% after the FDA said its experimental treatment for a group of bone marrow diseases was approvable but that it needed more information before allowing it on the market.
Latest news from Government/ Industry Regulation News from myHealthcareNews.com:
- PLC Systems to Show RenalGuard at Medica 2006
- National Public Health Summit Targets Cervical Cancer Elimination
- MediPurpose Announces Exclusive Distribution Agreement for Sangofer Blood Separation Product
- Portrait PSR3 by Rhytec named in TIME Magazine's 2006 Skin Technology Story
- Pharsight Invited to Present on Model-Based Drug Development rd Annual Australian Health and Medical Research Congress
- Spectrum Pharmaceuticals Announces Presentation of Ozarelix Data at the Congress of the Societe Internationale d'Urologie
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ
- Sector Election Boosts Stem Cells
- AUDIO From Medialink and AARP: Voters' Call for Change Signals New Directions for Health Care
- Schering-Plough CEO Calls on New Congress to 'Do What Is Right' for the Patient, Calls for 'Scorecards' to Rate Managed Care Performance